Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PYGB | P11216 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037239 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15721245 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8523079 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL16547556 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15265730 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959424 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969695 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4604138 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15264856 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2853262 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-03-17 | — | — | US | claimed |
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-08-27 | — | — | US | claimed |
| EP-2827899-B1 | POLYSACCHARIDE ANTIGEN-GLYCOLIPID CONJUGATE VACCINES | MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V (DE) | 2015-08-05 | — | — | EP | claimed |
| EP-2827899-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-01-28 | — | — | EP | claimed |
| CN-104321079-A | Carbohydrate-glycolipid conjugate vaccines | MAX PLANCK GESELLSCHAFT | 2015-01-28 | — | — | CN | claimed |
| WO-2013178236-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2013-12-05 | — | — | WO | claimed |
| WO-2013139803-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-09-26 | — | — | WO | claimed |
| EP-1893041-A4 | FIBER FORTIFIED CEREALS, CEREAL BARS AND SNACKS AND METHODS FOR MAKING | HENRY H OTTENS MFG COMPANY INC (US) | 2009-05-13 | — | — | EP | claimed |
| EP-1893041-A1 | FIBER FORTIFIED CEREALS, CEREAL BARS AND SNACKS AND METHODS FOR MAKING | Henry H Ottens Manufacturing Company, Inc (US) | 2008-03-05 | — | — | EP | claimed |
| WO-2006138705-A1 | FIBER FORTIFIED CEREALS, CEREAL BARS AND SNACKS AND METHODS FOR MAKING | HENRY H OTTENS MANUFACTURING COMPANY, INC (US) | 2006-12-28 | — | — | WO | claimed |
| CN-114630911-B | Enzymatic process for the preparation of UDP-GlcNAc | 马克斯·普朗克科学促进学会 | 2024-06-28 | — | — | CN | disclosed |
| US-20240124911-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-04-18 | — | — | US | disclosed |
| EP-4103730-B1 | ENZYMATIC METHOD FOR PREPARATION OF CMP-NEU5AC | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-11795486-B2 | Enzymatic method for preparation of GDP-fucose | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-10-24 | — | — | US | disclosed |
| EP-3784792-B9 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX PLANCK GESELLSCHAFT (DE) | 2023-10-04 | — | — | EP | disclosed |
| WO-2013139803-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-09-26 | — | — | WO | disclosed |
| EP-1893041-A4 | FIBER FORTIFIED CEREALS, CEREAL BARS AND SNACKS AND METHODS FOR MAKING | HENRY H OTTENS MFG COMPANY INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1893041-A1 | FIBER FORTIFIED CEREALS, CEREAL BARS AND SNACKS AND METHODS FOR MAKING | Henry H Ottens Manufacturing Company, Inc (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138705-A1 | FIBER FORTIFIED CEREALS, CEREAL BARS AND SNACKS AND METHODS FOR MAKING | HENRY H OTTENS MANUFACTURING COMPANY, INC (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2002005667-A2 | OLIGOSACCHARIDE ENCAPSULATED MINERAL AND VITAMIN INGREDIENTS | GENERAL MILLS, INC. (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238597-A1 | CARBOHYDRATE-GLYCOLIPID CONJUGATE VACCINES | STT3B, STT3A, DDOST | MEN1 2616/4885KMT2A 2780/4885PYGB 553/4885 |
| US-10588962-B2 | Carbohydrate-glycolipid conjugate vaccines | STT3B, STT3A, DDOST | MEN1 2616/4885KMT2A 2780/4885PYGB 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.